SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer

Journal of Clinical Investigation

Volumn 122, Issue 5, 2012, Pages 1895-1906

  Wang, Chu An ^a   Jedlicka, Paul ^a   Patrick, Aaron N ^a   Micalizzi, Douglas S ^a   Lemmer, Kimberly C ^a,b   Deitsch, Erin ^a   Casás Selves, Matias ^a   Harrell, J Chuck ^a,c   Ford, Heide L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR SIX1; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; DISEASE MODEL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR BURDEN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84860172725     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59858     Document Type: Article

References (53)

1. Seo HC, Curtiss J, Mlodzik M, Fjose A. Six class homeobox genes in drosophila belong to three distinct families and are involved in head development. Mech Dev. 1999;83(1-2):127-139. (Pubitemid 29302087)
2. Li X, et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature. 2003;426(6964):247- 254. (Pubitemid 37463137)
3. Yu YL, Davicioni E, Triche TJ, Merlino G. The homeoprotein Six1 transcriptionally activates multiple protumorigenic genes but requires Ezrin to promote metastasis. Cancer Res. 2006;66(4):1982-1989.
4. Kobayashi H, Kawakami K, Asashima M, Nishinakamura R. Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects. Mech Dev. 2007;124(4):290-303. (Pubitemid 46400394)
5. Yu Y, Davicioni E, Triche TJ, Merlino G. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 2006;66(4):1982-1989.
6. Coletta RD, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004;101(17):6478-6483. (Pubitemid 38585999)
7. Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res. 2010;70(24):10371-10380.
8. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 2008;68(7):2204-2213. (Pubitemid 351521793)
9. McCoy EL, et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 2009;119(9):2663-2677.
10. Micalizzi DS, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest. 2009;119(9):2678- 2690.
11. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004;10(2):175-181. (Pubitemid 38524888)
12. Ng KT, et al. Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int J Cancer. 2010;127(4):859-872.
13. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47(1):28-51. (Pubitemid 27050848)
14. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-187. (Pubitemid 19032001)
15. Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. 2010;17(4):229-251.
16. Mandriota SJ, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20(4):672-682. (Pubitemid 32167632)
17. Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009;13(8A):1405-1416.
18. Bjorndahl M, et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A. 2005;102(43):15593-15598. (Pubitemid 41528101)
19. Cao R, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6(4):333-345. (Pubitemid 39361435)
20. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio and lymphangiogenesis. Br J Cancer. 2007;96(7):1092-1100. (Pubitemid 46608319)
21. Nakamura Y, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat. 2005;91(2):125-132. (Pubitemid 40684925)
22. Gu Y, Qi X, Guo S. Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis. 2008;25(7):717-725.
23. Karkkainen MJ, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5(1):74-80. (Pubitemid 38081471)
24. Baldwin ME, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25(6):2441-2449. (Pubitemid 40354637)
25. Karpanen T, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61(5):1786-1790. (Pubitemid 32691984)
26. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer. 2002;98(6):946-951. (Pubitemid 34286696)
27. Skobe M, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7(2):192-198. (Pubitemid 32148486)
28. Heanue TA, et al. Synergistic regulation of vertebrate muscle development by Dach2, Eya2, and Six1, homologs of genes required for Drosophila eye formation. Genes Dev. 1999;13(24):3231-3243. (Pubitemid 30030445)
29. Affolter M, Slattery M, Mann RS. A lexicon for homeodomain-DNA recognition. Cell. 2008;133(7):1133-1135. (Pubitemid 351852921)
30. Maruyama K, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115(9):2363-2372. (Pubitemid 41266198)
31. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399-1405.
32. Cao Y, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95(24):14389-14394. (Pubitemid 28549377)
33. Miller BE, Roi LD, Howard LM, Miller FR. Quantitative selectivity of contact-mediated intercellular communication in a metastatic mouse mammary tumor line. Cancer Res. 1983;43(9):4102-4107. (Pubitemid 13041037)
34. Behbakht K, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007;67(7):3036-3042. (Pubitemid 46724840)
35. Yang J, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl. 2006;8(2):169-175. (Pubitemid 43349187)
36. Ueda M, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer. 2002;98(3):335-343. (Pubitemid 34188675)
37. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92(3):556-568.
38. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat. 2001;66(2):159-164. (Pubitemid 32521422)
39. Enholm B, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;14(20):2475-2483. (Pubitemid 27268166)
40. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Upregulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem. 2003;278(8):5750-5759.
41. Dadiani M, et al. Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. Cancer Res. 2006;66(16):8037-8041. (Pubitemid 44299168)
42. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009;69(1):349-357.
43. Padera TP, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296(5574):1883-1886. (Pubitemid 34596277)
44. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 2004;64(13):4400-4404. (Pubitemid 38856908)
45. Williams CS, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol. 2003;200(2):195-206. (Pubitemid 36748028)
46. He Y, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94(11):819-825. (Pubitemid 34705053)
47. Burton JB, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008;68(19):7828-7837.
48. Laclef C, Hamard G, Demignon J, Souil E, Houbron C, Maire P. Altered myogenesis in Six1-deficient mice. Development. 2003;130(10):2239-2252. (Pubitemid 36656718)
49. Laclef C, Souil E, Demignon J, Maire P. Thymus, kidney and craniofacial abnormalities in Six 1 deficient mice. Mech Dev. 2003;120(6):669-679. (Pubitemid 36794448)
50. Ozaki H, et al. Six4, a putative myogenin gene regulator, is not essential for mouse embryonal development. Mol Cell Biol. 2001;21(10):3343-3350. (Pubitemid 32381770)
51. Grifone R, et al. Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo. Development. 2005;132(9):2235-2249. (Pubitemid 40744482)
52. Coletta RD, et al. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. BMC Dev Biol. 2010;10:4.
53. Kang Y, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537-549. (Pubitemid 36808649)